1)図説わが国の慢性透析療法の現況.日本透析医学会 統計調査委員会.2013年12月31日現在
|
|
|
2)Ieiri N, Hotta O, Sato T, et al. Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy. Clin Exp Nephrol. 2012; 16: 122-9
|
|
|
3)Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007; 71: 1148-54
|
|
|
4)Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008; 19: 1008-14
|
|
|
5)Novak J, Julian BA, Mestecky J, et al. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol. 2012; 34: 365-82
|
|
|
6)Mestecky J, Raska M, Julian BA, et al. IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol. 2013; 24; 8: 217-40
|
|
|
7)Matousovic K, Novak J, Yanagihara T, et al. IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant. 2006; 21: 2478-84
|
|
|
8)Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011; 22: 1795-803
|
|
|
9)Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012; 82: 790-6
|
|
|
10)Camilla R, Suzuki H, Daprà V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol. 2011; 6: 1903-11
|
|
|
11)Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012; 23: 1579-87
|
|
|
12)Wada Y, Ogata H, Takeshige Y, et al. Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy. Clin Exp Nephrol. 2013; 17: 73-82
|
|
|
13)Suzuki Y, Matsuzaki K, Suzuki H, et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol. 2014; 18: 770-7
|
|
|
14)Nakata J, Suzuki Y, Suzuki H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One. 2014; 9: e89707
|
|
|
15)Suzuki Y, Suzuki H, Makita Y, et al. Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers. Int J Nephrol Renovasc Dis. 2014; 7: 409-14
|
|
|
16)Yanagawa H, Suzuki H, Suzuki Y, et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One. 2014; 9: e98081
|
|
|
17)Yasutake J, Suzuki Y, Suzuki H, et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015; 30: 1315-21
|
|
|
18)Lan HY, Paterson DJ, Atkins RC. Initiation and evolution of interstitial leukocytic infiltration in experimental glomerulonephritis. Kidney Int. 1991; 40: 425-33
|
|
|
19)Bohle A, Wehrmann M, Bogenschutz O, et al. The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract. 1992; 188: 908-24
|
|
|
20)Suzuki H, Suzuki Y, Yamanaka T, et al. Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23. J Am Soc Nephrol. 2005; 16: 1289-99
|
|
|
21)Okazaki K, Suzuki Y, Otsuji M, et al. Development of a model of early-onset IgA nephropathy. J Am Soc Nephrol. 2012; 23: 1364-74
|
|
|
22)Muso E, Yoshida H, Takeuchi E, et al. Enhanced production of glomerular extracellular matrix in a new mouse strain of high serum IgA ddY mice. Kidney Int. 1996; 50: 1946-57
|
|
|
23)Kajiyama T, Suzuki Y, Kihara M, et al. Different pathological roles of toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy. Clin Dev Immunol. 2011; 2011: 819646
|
|
|
24)Aizawa M, Suzuki Y, Suzuki H, et al. Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy. PLoS One. 2014; 9: e95365
|
|
|
25)Kim YG, Alvarez M, Suzuki H, et al. Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS One. 2015; 10: e0137044
|
|
|
26)Hashimoto A, Suzuki Y, Suzuki H, et al. Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am J Pathol. 2012; 181: 1338-47
|
|
|
27)Yamaji K, Suzuki Y, Suzuki H, et al. The kinetics of glomerular deposition of nephritogenic IgA. PLoS One. 2014; 9: e113005
|
|
|
28)Song KH, Park J, Park JH, et al. Fractalkine and its receptor mediate extracellular matrix accumulation in diabetic nephropathy in mice. Diabetologia. 2013; 56: 1661-9
|
|
|
29)Yoshimoto S, Nakatani K, Iwano M, et al. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis. 2007; 50: 47-58
|
|
|
30)Cox SN, Sallustio F, Serino G, et al. Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int. 2012; 82: 548-60
|
|
|
31)Morimura S, Sugaya M, Sato S. Interaction between CX3CL1 and CX3CR1 regulates vasculitis induced by immune complex deposition. Am J Pathol. 2013; 182: 1640-7
|
|
|
32)Santiago-Raber ML, Baudino L, Alvarez M, et al. TLR7/9-mediated monocytosis and maturation of Gr-1(hi) inflammatory monocytes towards Gr-1(lo) resting monocytes implicated in murine lupus. J Autoimmun. 2011; 37: 171-9
|
|
|
33)Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007; 204: 3037-47
|
|
|
34)Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007; 317: 666-70
|
|
|
35)Cox SN, Serino G, Sallustio F, et al. Altered monocyte expression and expansion of non-classical monocyte subset in IgA nephropathy patients. Nephrol Dial Transplant. 2015; 30: 1122-232
|
|
|
36)Tsuruga K, Aizawa T, Watanabe S, et al. Expressions of mRNA for innate immunity-associated functional molecules in urinary sediment in IgA nephropathy. Nephrology (Carlton). 2015; 20: 916-21
|
|
|
37)Suzuki Y, Suzuki H, Yasutake J, et al. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting. Expert Opin Biol Ther. 2015; 15: 583-93
|
|
|